Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

15.79
Delayed Data
As of Jan 18
 -0.02 / -0.13%
Today’s Change
15.41
Today|||52-Week Range
41.75
-5.28%
Year-to-Date
Casualty List Has Done Well; Here's the Latest
Jan 18 / GuruFocus News - Paid Partner Content
Better Buy: Myriad Genetics vs. Exact Sciences
Jan 09 / MotleyFool.com - Paid Partner Content
Why Myriad Genetics, Inc. Stock Dropped 61% in 2016
Jan 13 / MotleyFool.com - Paid Partner Content
Myriad Genetics: Evidence Street Reviews EndoPredict Test
Jan 06 / Zacks.com - Paid Partner Content
Why Exact Sciences' Stock Could Go Much Higher
Jan 13 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close15.81
Today’s open15.44
Day’s range15.41 - 15.86
Volume1,423,108
Average volume (3 months)1,480,273
Market cap$1.1B
Dividend yield--
Data as of 01/18/2017

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-38.83%
Earnings growth (next 5 years)-3.00%
Revenue growth (last year)+4.25%
P/E ratio12.4
Price/Sales2.98
Price/Book1.46

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...+0.04+0.14%
VIVOMeridian Bioscience ...+0.15+0.89%
QDELQuidel Corp-0.02-0.10%
ALRPRBAlere Inc-0.30-0.09%
Data as of 01/18/2017

Financials

Next reporting dateFebruary 7, 2017
EPS forecast (this quarter)$0.24
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts


Search for Jobs